Hydrops Fetalis

Publisher Website
Google Scholar
Abstract
INNOVATIONS in management of hemolytic disease of the newborn promise salvage of some otherwise doomed infants by judicious choice of dates of delivery and perinatal treatment.1 , 2 The advent of fetal transfusion presages an era of more complex therapeutic manipulations of the young fetus while he is still sheltered within the uterus. When hydrops develops, these measures are almost always futile. It appears that the administration of immune globulin to the mother immediately after delivery prevents initial sensitization to the Rhesus antigen.3 , 4 However, universal application of this prophylactic procedure cannot be expected for some years. Furthermore, many women of childbearing age . . .

This publication has 11 references indexed in Scilit: